These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 18763674)

  • 41. [Pharmacoepidemiology].
    Hallas J; Sørensen HT
    Ugeskr Laeger; 2005 May; 167(20):2186-90. PubMed ID: 15987081
    [No Abstract]   [Full Text] [Related]  

  • 42. Care ideologies reflected in 4 conceptions of pharmaceutical care.
    Björkman IK; Bernsten CB; Sanner MA
    Res Social Adm Pharm; 2008 Dec; 4(4):332-42. PubMed ID: 19064240
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The dentist and prescription drug abuse.
    Balevi B; Breen L; Krasnowski J
    J Can Dent Assoc; 1996 Jan; 62(1):56-60. PubMed ID: 8673939
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advances in the pharmacogenomics of adverse drug reactions.
    Alvarado I; Wong ML; Licinio J
    Pharmacogenomics J; 2002; 2(5):273. PubMed ID: 12439730
    [No Abstract]   [Full Text] [Related]  

  • 45. Can a multidisciplinary initiative to increase adverse drug reaction reporting work?
    Perkerson KA; Quercia RA; Goldman M; Goddu G; Coleman CI
    Conn Med; 2004 May; 68(5):281-4. PubMed ID: 15171264
    [No Abstract]   [Full Text] [Related]  

  • 46. Monitoring for adverse drug events.
    Kennedy DL; Goldman SA
    Am Fam Physician; 1997 Nov; 56(7):1718, 1721. PubMed ID: 9371003
    [No Abstract]   [Full Text] [Related]  

  • 47. Spontaneous reporting of adverse drug events by Korean regional pharmacovigilance centers.
    Shin YS; Lee YW; Choi YH; Park B; Jee YK; Choi SK; Kim EG; Park JW; Hong CS
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):910-5. PubMed ID: 19621345
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The use of an integrated opioid and medical marijuana prescription drug monitoring program.
    Rickles NM; Wakai S; Karim-Nejad L
    J Am Pharm Assoc (2003); 2021; 61(4):408-417. PubMed ID: 33903060
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Additional information on adverse drug reaction reporting.
    Schneiweiss F
    Am J Hosp Pharm; 1989 May; 46(5):922. PubMed ID: 2729299
    [No Abstract]   [Full Text] [Related]  

  • 50. [The international system of drug control].
    Barbadoro E
    Boll Chim Farm; 1990 Mar; 129(3):140-3. PubMed ID: 2245002
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Telepharmacology in clinical practice?
    Leskosek B; Ferk P
    Stud Health Technol Inform; 2013; 192():1220. PubMed ID: 23920994
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Can drug design inhibit abuse?
    Coleman JJ; Bensinger PB; Gold MS; Smith DE; Bianchi RP; DuPont RL
    J Psychoactive Drugs; 2005 Dec; 37(4):343-62. PubMed ID: 16480162
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A report by a working party 1975. Council of Europe European Public Health Community. Abuse of medicines. II. Prescription medicines.
    Drug Intell Clin Pharm; 1976 Feb; 10(2):94-110. PubMed ID: 10316507
    [No Abstract]   [Full Text] [Related]  

  • 54. [The battle against adverse effects of drugs goes on. Comments to a survey].
    Boréus L
    Lakartidningen; 2004 Mar; 101(11):1016-8. PubMed ID: 15055125
    [No Abstract]   [Full Text] [Related]  

  • 55. The growing issue of medication-related adverse events.
    Giaquinta D
    Manag Care Interface; 2007 Oct; 20(10):35-6. PubMed ID: 18405205
    [No Abstract]   [Full Text] [Related]  

  • 56. The Welsh Adverse Drug Reactions Scheme: experience of a UK regional monitoring centre.
    Houghton JE; Pinto Pereira LM; Woods FJ; Richens A; Routledge PA
    Adverse Drug React Toxicol Rev; 1996 Jun; 15(2):93-107. PubMed ID: 8836315
    [No Abstract]   [Full Text] [Related]  

  • 57. [Prescription of drugs from medico-psychological points of view].
    Langen D
    Munch Med Wochenschr; 1970 Dec; 112(49):2215-9. PubMed ID: 5536809
    [No Abstract]   [Full Text] [Related]  

  • 58. Accelerating statistical research in drug safety.
    Bilker W; Gogolak V; Goldsmith D; Hauben M; Herrera G; Hochberg A; Jolley S; Kulldorff M; Madigan D; Nelson R; Shapiro A; Shmueli G
    Pharmacoepidemiol Drug Saf; 2006 Sep; 15(9):687-8. PubMed ID: 16941519
    [No Abstract]   [Full Text] [Related]  

  • 59. Publicly accessible pharmacovigilance databases.
    Prescrire Int; 2012 Apr; 21(126):99. PubMed ID: 22515136
    [No Abstract]   [Full Text] [Related]  

  • 60. OBRA '90 pharmacy system survey results.
    Cataldo R
    Am Pharm; 1994 Jun; NS34(6):18-9. PubMed ID: 8059681
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.